Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Tetrahydrobiopterin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used along with diet changes for long-term treatment of a certain inherited disorder (phenylketonuria-PKU).
Nutraceutical composition and method of use for treatment / prevention of cancer
InactiveUS20070248693A1Function increaseAbility to createBiocideAlgae medical ingredients1,4-BenzoquinonePantothenic acid
The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.
Owner:MAZZIO ELIZABETH +1
Topical management of ocular and periocular conditions
Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide / endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents are tetrahydrobiopterin, R-alpha-lipoic acid, coenzyme Q10, 17 alpha-estradiol, and glutathione.
Owner:CHRONORX
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative
Owner:NYCOMED GMBH
Nutraceutical composition and method of use for treatment / prevention of cancer
ActiveUS20100209388A1Easy to understandReduce weightOrganic active ingredientsBiocideMyrrh1,4-Benzoquinone
The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.
Owner:FLORIDA A&M UNIVERSITY
Stable Tablet Formulation
ActiveUS20070270581A1Disintegrates quicklyImprove usabilityOrganic active ingredientsNervous disorderMedicineTetrahydrobiopterin
The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.
Owner:BIOMARIN PHARMA INC
Methods and Compositions for the Treatment of Attention Deficit Hyperactivity Disorder and Hyperphenylalanemia
Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with ADHD that includes administering a tetrahydropterin to the patient. Compositions for the treatment of ADHD are also described.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
New system and kit for screening and diagnosing phenylketonuria
ActiveCN105755109ALow costImprove throughputMicrobiological testing/measurementGenes mutationImage resolution
The invention discloses a new system for screening and diagnosing phenylketonuria.41 common phenylalanine hydroxylase gene mutation sites and 4 most common 6-pyruvoyl tetrahydrobiopterin synthetase (PTPS) gene (PTS) mutation sites are screened to form the gene mutation detection system of phenylketonuria.The system is low in cost and high in throughput.Compared with the prior art, the system has the advantages that most mutation sites can be detected in one system, and 45 mutation sites can be detected; the comprehensive cost is the lowest, and the total cost of the system is lower than built methods using the DNA chip technology, the 'molecular switch' technology, the high-resolution melting curve method and the SNaPShot technology to detect PAH gene mutation; most mutation sites can be detected, the number of the detected mutation sites is twice as the number of the detected PAH gene mutation sites of the high-resolution melting curve method built by Xiamen University, the number of the detected mutation sites is 4 times as the number of the detected mutation sites of the DNA chip technology and the SNaPShot technology, and the number of the detected mutation sites is 6 times as the number of the detected mutation sites of the 'molecular switch' technology.
Owner:SUZHOU MUNICIPAL HOSPITAL +1
Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with ADHD that includes administering a tetrahydropterin to the patient. Compositions for the treatment of ADHD are also described.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
InactiveUS20070254288A1Amenable to multiplexingAmenable to high-throughput analysisNervous disorderMicrobiological testing/measurementDiseaseWhite blood cell
Disclosed herein are methods for determining whether a subject possesses altered pain sensitivity an altered risk of developing acute or chronic pain, or diagnosing a tetrahydrobiopterin (BH4)-related disorder or a propensity thereto. These methods are based on the discovery of GCH1 and KCNS1 allelic variants that are associated with altered pain sensitivity and altered risk of developing acute or chronic pain, and the discovery that a GCH1 “pain protective haplotype” is associated with decreased upregulation of BH4 synthesis in treated leukocytes.
Owner:THE GENERAL HOSPITAL CORP +1
Microorganisms for the production of 5-hydroxytryptophan
InactiveUS20150037849A1Cost-efficient productionBacteriaHydrolasesMicroorganismTryptophan hydroxylase
Recombinant microbial cells and methods for producing 5-hydroxytryptophan (5HTP) using such cells are described. More specifically, the recombinant microbial cell comprises an exogenous gene encoding an L-tryptophan hydroxylase, and means for providing tetrahydrobiopterin (THB). Related sequences and vectors for use in preparing such recombinant microbial cells are also described.
Owner:DANMARKS TEKNISKE UNIV
Organic preserving solution and its preparation method
InactiveCN101167450ASlow down biochemical reactionsDelay dissipationDead animal preservationSodium lactateMannitol
The invention belongs to the technology of medical biology and relates to organ preservative fluid and the method for making same. The procedure to prepare 1000ml of the fluid is as follows, tetrahydrobiopterin 1.57mg and diazoxide 6.92mg are dissolved in 1ml of dimethyl sulfoxide to act as mother liquid, CaCl2 of 0.1mol / L is prepared for backup, double distilled water 800ml is charged in a container of 1000ml, KCl 1.12g, MgCl2 2.64g, manna sugar 10.93g, histidine 4.63g, glutathion 0.92g and glutavene 3.74g are sequentially charged and agitated to limpidity, 6.90ml of sodium lactate is charged and agitated to limpidity, CaCl2 2.5ml of 0.1mol / L is charged and agitated to limpidity, and backup liquid and mother liquid are charged and agitated to limpidity. The pH is adjusted to 7.3-7.5, the osmotic pressure is adjusted to 320Osm / L, and the volume of double distilled water is set to 1000ml. The fluid is stored in low temperature of 4 DEG C.
Owner:ZHEJIANG UNIV
Stable compositions of tetrahydrobiopterin
The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.
Owner:DIPHARMA SA
L-citrulline for treating endothelial dysfunction and erectile dysfunction
ActiveUS20110044965A1Cure endothelial dysfunctionIncreased endogenous productionUrea derivatives preparationBiocideEndothelial dysfunctionErectile function
L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of Viscum album, NADPH, tetrahydrobiopterin, folic acid and mixtures thereof.
Owner:ANDROSYST
Stable compositions of tetrahydrobiopterin
The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.
Owner:DIPHARMA SA
Microorganisms for efficient production of melatonin and related compounds
Recombinant microbial cells and methods for producing 5HTP, melatonin and related compounds using such cells are described. More specifically, the recombinant microbial cell may comprise exogenous genes encoding one or more of an L-tryptophan hydroxylase, a 5-hydroxy-L-tryptophan decarboxylyase, a serotonin acetyltransferase, an acetylserotonin O-methyltransferase; and means for providing tetrahydrobiopterin (THB), and can be further genetically modified to enrich one or more of tryptophan, S-adenosyl-L-methinonine and acetyl coenzyme A. Related sequences and vectors for use in preparing such recombinant microbial cells are also described.
Owner:DANMARKS TEKNISKE UNIV
Effervescent tablet containing sapropterin dihydrochloride
InactiveCN104257623AHigh hardnessNo reduction in friabilityOrganic active ingredientsMetabolism disorderEffervescent tabletMedicine
The invention belongs to the pharmaceutical field, and in particular relates to an effervescent tablet containing sapropterin dihydrochloride. The effervescent tablet comprises 4-12wt% of sapropterin dihydrochloride, 5-40wt% of an acid source, 9-50wt% of an alkali source, 0.1-5wt% of an antioxidant, 5-50wt% of filler, 1-5wt% of a disintegrating agent, 1-4wt% of a binding agent, 1-5wt% of a wetting agent and 0.5-5wt% of a flavoring agent. The effervescent tablet disclosed by the invention is applicable to hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4) of the adult and children older than 4-years old. The effervescent tablet disclosed by the invention is quick to disintegrate, and a foaming amount is more than 10ml; a formed solution is good in appearance, and high in oral compliance to children; and compared to an originally developed preparation, absorption and in-vivo distribution are not changed.
Owner:中盛特医食品(汕头)有限公司
Stable tablet formulation
ActiveUS20080207626A1Disintegrates quicklyImprove usabilityBiocideNervous disorderMedicineTetrahydrobiopterin
The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.
Owner:BIOMARIN PHARMA INC
Uses of tetrahydrobiopterin and derivatives thereof
ActiveUS7863275B2Restoring gut motilityHigh activityBiocideDigestive systemEndocrinologyTetrahydrobiopterin
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Biomarker for abdominal aortic aneurysm
ActiveUS20140308686A1Effective treatmentIncreased and decreasedMicrobiological testing/measurementDisease diagnosisTest sampleEffective treatment
Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and / or for treatment for AAA.
Owner:RGT UNIV OF CALIFORNIA
L-citrulline for treating endothelial dysfunction and erectile dysfunction
ActiveUS8802162B2Improve permeabilityImprove bioavailabilityBiocideOrganic active ingredientsEndothelial dysfunctionAqueous extract
L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of Viscum album, NADPH, tetrahydrobiopterin, folic acid and mixtures thereof.
Owner:ANDROSYST
Application and drug of tetrahydrobiopterin
PendingCN110354133AImprove proliferative abilityReduce the effects of lung radiation damageOrganic active ingredientsRespiratory disorderTreatment effectRadiation injury
The invention relates to application and a drug of tetrahydrobiopterin. It is found that tetrahydrobiopterin (BH4) has the prevention and treatment effect on radiation injury of human lung cells and animal model lung tissues, and can enhance oxidation resistance of the cells and cell proliferation capacity after radiation. The tetrahydrobiopterin or the drug containing the tetrahydrobiopterin canbe used for preventing and treating human acute lung radiation injury, and has the important significance and application value in coping with nuclear and radiation accidents, nuclear emergencies, reduction of the lung radiation injury effects on tumor radiation patients and the like.
Owner:鞍山市肿瘤医院 +1
Core-shell structural anode catalyst for direct borohydride fuel cells and preparation method thereof
InactiveCN102380400BGood anodic oxidation performanceIncrease profitCell electrodesMetal/metal-oxides/metal-hydroxide catalystsNano catalystNitrogen gas
Owner:TAIYUAN UNIV OF TECH
A novel treatment regimen involving sapropterin dihydrochloride
The invention relates to an improved tetrahydrobiopterin formulation for treating patients affected by hyperphenylalaninemia. More specifically, the formulation of the invention permits a prolonged residence of tetrahydrobiopterin in the plasma, and / or a higher concentration of sapropterin in the plasma, enabling notably the treatment of HPA patients that would usually not be classified as responders to tetrahydrobiopterin loading test, and therefore left without any pharmacological treatment opportunity, but only with a strictly controlled protein diet.
Owner:DIPHARMA SA
Use of a Nitric Oxide Synthase Modulator for the Treatment of Cardiac Indications
InactiveUS20100004248A1Restore anti-adrenergic effectAugment physiologic regulation of heart functionBiocideAnimal repellantsDiseaseHeart disease
The invention features compositions and methods for modulating NOS that are useful for the prevention and treatment of cardiac diseases and disorders, including cardiac hypertrophy and cardiac dilation. In particular, the invention provides compositions comprising tetrahydrobiopterin (BH4), alone or in combination with one or more additional compounds.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Use of bh4 for the treatment of respiratory diseases
The invention describes the use of Tetrahydrobiopterin (BH4) or derivatives thereof for the treatment of COPD. In a preferred embodiment, BH4 or derivates thereof are combined with arginine or derivatives thereof.
Owner:ALTANA PHARMA
Organic preserving solution and its preparation method
InactiveCN100546472CProlong survival timeImprove survival rateDead animal preservationSodium lactateHistidine
The invention belongs to medical biology technology, and relates to an organ preservation solution and its preparation. According to the preparation steps per 1000ml, it comprises: taking 1.57mg of tetrahydrobiopterin and 6.92mg of diazoxide and dissolving them in 1ml of dimethyl sulfoxide As a mother liquor; prepare 0.1mol / L CaCl210ml for later use; add 800ml double distilled water into a 1000ml container, add KCl 1.12g, MgCl22.64g, mannitol 10.93g, histidine 4.63g, glutathione 0.92g, Sodium glutamate 3.74g, stir until clear; add sodium lactate 6.90ml, stir until clear; add 0.1mol / L CaCl22.5ml, stir until clear; add stock solution and mother liquor, stir until clear. The pH was adjusted to 7.3-7.5, the osmotic pressure was adjusted to 320Osm / L, and the volume was adjusted to 1000ml with double distilled water. Store at 4°C for low temperature storage.
Owner:ZHEJIANG UNIV
Uses of tetrahydrobiopterin and derivatives thereof
ActiveUS20080207579A1Restoring gut motilityHigh activityBiocideMicrobiological testing/measurementHormones regulationCvd risk
The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Proteins with pteridine glycosyltransferase activity and analysis method using the same
InactiveUS8658382B2Low levelPeptide/protein ingredientsLaboratory glasswaresGlycosyltransferase activityAnalysis method
The present invention relates to proteins with pteridine glycosyltransferase activity and an analysis method using the same. Since the proteins glycate tetrahydrobiopterin selectively through an enzyme reaction, the method enables quantitative analysis of tetrahydrobiopterin and oxides thereof at the same time or quantitative analysis of tetrabiopterin selectively.
Owner:INJE UNIV IND ACADEMIC COOP FOUND
Popular searches
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com